Centauri Therapeutics
Latest round
- Series A
Last raised
- Feb 2026
Total raised
- $73M
Investors
- 7
About Centauri Therapeutics
Centauri Therapeutics Limited specializes in immunotherapy solutions, leveraging its proprietary Alphamer® platform to redirect existing antibodies against severe infections. Founded in 2014 in London, UK, the company has undergone various strategic developments, focusing primarily on European markets. This platform redirects naturally existing antibodies to combat life-threatening infections, particularly focusing on Gram-negative bacterial infections. The Alphamer® technology is clinically validated, underscoring its effectiveness in treating vulnerable patient populations. The primary end users are healthcare providers and clinical institutions seeking advanced therapeutic options. While the initial focus is on European markets, there are plans for potential expansion into North America and other regions. Revenue generation may stem from collaborations, grants, and potential licensing agreements for its proprietary technology. The company's flagship products are positioned for direct marketing to healthcare providers, potentially involving sales agreements or collaborations with pharmaceutical companies.
Who invested in Centauri Therapeutics
7 investors across 2 rounds
See all investors in Centauri Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Centauri Therapeutics
Who invested in Centauri Therapeutics?
Centauri Therapeutics has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Centauri Therapeutics raised?
Centauri Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Centauri Therapeutics last raise money?
Centauri Therapeutics's most recent round on record is a Series A, in Feb 2026.
What does Centauri Therapeutics do?
Centauri Therapeutics Limited specializes in immunotherapy solutions, leveraging its proprietary Alphamer® platform to redirect existing antibodies against severe infections.
Where is Centauri Therapeutics headquartered?
Centauri Therapeutics is headquartered in London, UK.
Which VCs invest in companies like Centauri Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Centauri Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Centauri Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.